Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Mr. Sandesh C. Seth M.B.A., M.S.

Chairman & Chief Executive Officer

Dr. David  Gould

Senior Vice President of Corporate Development & Corporate Affairs

Mr. Steven  O'Loughlin BS

Chief Financial Officer & Corporate Secretary

Ms. Sunitha  Lakshminarayanan

Senior Vice President, Head of CMC & Product Development

Dr. Paul  Diamond Esq., Ph.D.

Vice President of Patent & Legal Counsel

Dr. Bernie  Cunningham P.M.P., Ph.D.

Executive Director of Clinical Supply Chain & Logistics and CMC Project Management

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. Δομή της διοίκησης

Πληροφορίες για τη διοίκηση